All 1 tracked stories fall under one category: regulation. Embecta Corp. is most often covered alongside ADMA Biologics, Inc., which appears in 1 of these 1 story. Each story carries 4 original sources on average, compared with 4.6 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Embecta Corp.
All 1 tracked stories fall under one category: regulation. Embecta Corp. is most often covered alongside ADMA Biologics, Inc., which appears in 1 of these 1 story. Each story carries 4 original sources on average, compared with 4.6 for the broader beat in this window. Their average consequence score of 7 runs above the beat's 6.5 for that window. We currently track 1 Legal story that mention Embecta Corp., all published on July 12, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 33 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Embecta Corp.. Shared-story counts are live from our verified record — not editorial picks.
BFA Law launches coordinated class actions against Microsoft, ADMA, Insulet, and Embecta over product-related misrepresentations, with lead plaintiff deadlines in August.